Advancements in Cardiovascular Molecular Research 🧬

Created using ChatSlide

This presentation will delve into the evolving landscape of PCSK9 inhibition, focusing on its role in LDL regulation and promising therapeutic approaches, including oral inhibitors and in vivo gene editing. It highlights the outcomes of recent studies like the VERVE-102 and HEART-2, analyzing findings from a 2026 meta-analysis and assessing the efficacy and safety of current Phase 2/3 drugs. The discussion will explore the methodology and precision in gene editing using ABE 8.8, and...